GlassScriptPhysician profile
Janet N Wallace
NPI 1023001138
$4,132.32
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $826 · 2020: $301 · 2021: $963 · 2022: $1,079 · 2023: $577 · 2024: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $750.31 | 2019-2024 | |
| Abbvie INC. | $617.74 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $544.63 | 2019-2024 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $534.61 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $377.67 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $277.42 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $179.76 | 2022 | |
| Merck Sharp & Dohme LLC | $154.00 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $126.50 | 2019-2021 | |
| Lilly USA, LLC | $104.63 | 2019-2021 | |
| Amarin Pharma, INC. | $75.92 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.25 | 2022 | |
| Boston Scientific Corporation | $44.24 | 2023 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceuticals, INC. | $42.43 | 2021 | |
| Assertio Therapeutics, INC. | $37.50 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $36.05 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $35.63 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $23.14 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.45 | 2022 | |
| Astellas Pharma US INC | $18.69 | 2022 | |
| Shire North American Group INC | $17.62 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.28 | 2024 | Voquezna |
| Abbott Laboratories | $16.03 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.40 | 2023 | Livalo, Seglentis |
| Ironwood Pharmaceuticals, INC | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.